Ischemix is a privately-held company based in North Grafton, MA. The Company focuses on developing its family of cytoprotective compounds for serious neurological diseases and conditions. Ischemix’ lead compound, CMX-2043, for treatment of traumatic brain (TBI), has produced the strongest data of any preclinical compound in development for TBI. There are currently no drug therapies on the market for TBI.
In addition to the studies that the Company has completed to date, which are representative of moderate-to-severe injury in humans, Ischemix intends to commence a study of CMX-2043 in a preclinical model of mild TBI (also referred to as concussion), for treatment and prophylaxis targeted to individuals at higher risk of TBIs such as athletes and soldiers. The Company also intends to identify drug candidates for stroke from among its family of compounds. Consistent with the various patient populations it intends to serve, Ischemix is exploring alternative delivery systems for CMX-2043, which is currently in an injectable formulation.
CMX-2043 is a new chemical entity with a multi-modal activity that is well-suited for the complex condition of TBI. CMX-2043 is the subject of multiple issued composition of matter and method of use patents around the world.Learn more →